生物制药企业Perspective Therapeutics（股票代码：CATX）于2026年美国癌症研究协会（AACR）年会期间，公布了其核心靶向放射疗法[212PB]VMT-α-NET的1/2a期临床试验最新中期分析结果。该研究旨在评估这种创新疗法对神经内分泌肿瘤患者的治疗效果与安全性。
最新数据显示，[212PB]VMT-α-NET在特定患者群体中展现出令人鼓舞的抗肿瘤活性，且整体耐受性良好。临床试验中观察到的生物标志物反应进一步支持了该疗法的分子作用机制。这些阶段性成果为后续临床开发提供了重要依据。
公司表示将持续推进该疗法的临床研究进程，并计划根据试验进展与监管机构沟通后续开发策略。此次数据更新标志着Perspective Therapeutics在精准放射药物领域取得的关键进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.